ArticleAntimicrobial agents and chemotherapy2014
Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).The Cochrane database of systematic reviews · 2018Pooled it
- High-dose rifampicin and clarithromycin for 4 weeks versus standard-dose rifampicin and clarithromycin for 8 weeks to treat Buruli ulcer: An open-label, individually randomized, controlled trial in Ghana.PLoS neglected tropical diseases · 2026Trial
- Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.Lancet (London, England) · 2020Trial
- Local Heat Application for the Treatment of Buruli Ulcer: Results of a Phase II Open Label Single Center Non Comparative Clinical Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Trial
- TACTIC: A transfer learning framework to predict drug interactions in emerging pathogens.Cell reports methods · 2026Article
- Buruli ulcer.Nature reviews. Disease primers · 2025Review
- Antimicrobial resistant bacteria isolated from Buruli ulcer lesions in Ghana.PLoS neglected tropical diseases · 2025Article
- Improved protocols for isolation of Mycobacterium ulcerans from clinical samples.BMC microbiology · 2025Article
- Pharmacokinetics of extended-release clarithromycin in patients with Mycobacterium ulcerans infection.Scientific reports · 2024Article
- Transfer learning predicts species-specific drug interactions in emerging pathogens.bioRxiv : the preprint server for biology · 2024Article
- Clinical and microbiological predictors of healing in Buruli ulcer disease.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Mycobacterium ulcerans not detected by PCR on human skin in Buruli ulcer endemic areas of south eastern Australia.PLoS neglected tropical diseases · 2023Article
- Mycobacterium ulcerans culture results according to duration of prior antibiotic treatment: A cohort study.PloS one · 2023Article
- Evaluation of the fluorescent-thin layer chromatography (f-TLC) for the diagnosis of Buruli ulcer disease in Ghana.PloS one · 2022Article
- Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions.BMC microbiology · 2021Article
- Risk Factors Associated with Antibiotic Treatment Failure of Buruli Ulcer.Antimicrobial agents and chemotherapy · 2020Observational
- Barriers to Buruli ulcer treatment completion in the Ashanti and Central Regions, Ghana.PLoS neglected tropical diseases · 2020Article
- Pharmacologic management ofExpert review of clinical pharmacology · 2020Review
- Rapid Extraction Method ofDiagnostics (Basel, Switzerland) · 2019Article
- Providing insight into the incubation period of Mycobacterium ulcerans disease: two case reports.Journal of medical case reports · 2019Article
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
10 authors at 6 institutions in 5 countries.
Funding
Abstract
Buruli ulcer, an ulcerating skin disease caused by Mycobacterium ulcerans infection, is common in tropical areas of western Africa. We determined the clinical and microbiological responses to administration of rifampin and streptomycin for 2 weeks followed by administration of rifampin and clarithromycin for 6 weeks in 43 patients with small laboratory-confirmed Buruli lesions and monitored for recurrence-free healing. Bacterial load in tissue samples before and after treatment for 6 and 12 weeks was monitored by semiquantitative culture. The success rate was 93%, and there was no recurrence after a 12-month follow-up. Eight percent had a positive culture 4 weeks after antibiotic treatment, but their lesions went on to heal. The findings indicate that rifampin and clarithromycin can replace rifampin and streptomycin for the continuation phase after rifampin and streptomycin administration for 2 weeks without any apparent loss of efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.